^
Association details:
| Biomarker: | HLA-A*03 |
|---|---|
| Cancer: | Bladder Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Published date:
12/09/2021
Excerpt:
The aim of this epidemiological study was to determine the effect of HLA-A*03 as a biomarker for predicting response to immunotherapy....HLA-A*03 was associated in an additive manner with reduced overall survival after ICI treatment in...the JAVELIN Solid Tumour clinical trial for bladder cancer (HR 1·36 per HLA-A*03 allele, 1·01-1·85; p=0·047).
DOI:
10.1016/S1470-2045(21)00582-9
Trial ID:
